Home » Stocks » COLL

Collegium Pharmaceutical, Inc. (COLL)

Stock Price: $25.15 USD 0.39 (1.58%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 872.73M
Revenue (ttm) 321.23M
Net Income (ttm) 41.96M
Shares Out 34.95M
EPS (ttm) 1.18
PE Ratio 21.35
Forward PE 7.13
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $25.15
Previous Close $24.76
Change ($) 0.39
Change (%) 1.58%
Day's Open 24.76
Day's Range 24.62 - 25.43
Day's Volume 120,956
52-Week Range 15.66 - 26.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 202...

1 week ago - GlobeNewsWire

STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...

1 month ago - GlobeNewsWire

The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.

Other stocks mentioned: HRTX
1 month ago - The Motley Fool

STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today a...

2 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 –

2 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6,...

3 months ago - GlobeNewsWire

– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition –

5 months ago - GlobeNewsWire

STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Februar...

5 months ago - GlobeNewsWire

It's not every day that a company graduates to a slot in a high-profile stock index.

5 months ago - The Motley Fool

– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million –

6 months ago - GlobeNewsWire

Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and increase ...

8 months ago - Seeking Alpha

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Other stocks mentioned: ATNX
9 months ago - The Motley Fool

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Novembe...

9 months ago - GlobeNewsWire

These three health-related businesses are well positioned to provide market-beating gains.

Other stocks mentioned: INMD, PFE
9 months ago - The Motley Fool

STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today...

9 months ago - GlobeNewsWire

STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod...

10 months ago - GlobeNewsWire

STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, t...

10 months ago - GlobeNewsWire

STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod...

10 months ago - GlobeNewsWire

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 –

11 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, Augu...

1 year ago - GlobeNewsWire

Collegium Pharmaceuticals - Whether It's Too Cheap

1 year ago - Seeking Alpha

AMRX vs. COLL: Which Stock Is the Better Value Option?

Other stocks mentioned: AMRX
1 year ago - Zacks Investment Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Other stocks mentioned: AMRX
1 year ago - Zacks Investment Research

These are the two healthcare stocks that possess the best value for the greatest reward in May.

Other stocks mentioned: ABBV
1 year ago - The Motley Fool

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.

1 year ago - The Motley Fool

The Call On Collegium Pharmaceuticals

1 year ago - Seeking Alpha

COLL vs. NBIX: Which Stock Is the Better Value Option?

Other stocks mentioned: NBIX
1 year ago - Zacks Investment Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).

1 year ago - Zacks Investment Research

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% conve...

1 year ago - GlobeNewsWire

Investors aren't happy about the drugmaker's proposed senior convertible note offering.

1 year ago - The Motley Fool

Collegium Pharmaceutical: 2020 Could Be A Great Year

1 year ago - Seeking Alpha

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate...

1 year ago - GlobeNewsWire

The speciality pharmaceutical company purchased the full rights to an important drug product.

1 year ago - The Motley Fool

Collegium Pharmaceutical Inc. (NASDAQ: COLL) shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.

1 year ago - 24/7 Wall Street

– Financially Transformative Acquisition –

1 year ago - GlobeNewsWire

Prospects Appear Bright for Small Drug Industry in 2020

Other stocks mentioned: AMRX, KALV, MTNB
1 year ago - Zacks Investment Research

Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020

1 year ago - Seeking Alpha

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

1 year ago - Zacks Investment Research

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to C... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 7, 2015
CEO
Joseph Ciaffoni
Employees
234
Stock Exchange
NASDAQ
Ticker Symbol
COLL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 29.57, which is an increase of 17.57% from the latest price.

Price Target
$29.57
(17.57% upside)
Analyst Consensus: Buy